Nanoviricides (NNVC) Free Cash Flow (2010 - 2026)
Nanoviricides (NNVC) posted Free Cash Flow of -$2.1 million for Q1 2026, down 2.97% sequentially from -$2.0 million in Q4 2025, and down 3.42% YoY from -$2.1 million in Q1 2025.
Nanoviricides (NNVC) Free Cash Flow (2010 - 2026) Analysis & Trends
Nanoviricides has reported Free Cash Flow for 17 years, with the latest figure at -$2.1 million in Q1 2026.
- Quarterly Free Cash Flow fell 3.42% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.3 million (up 13.66% YoY) and the FY2025 annual result came in at -$8.5 million, down 30.82% from the prior year.
- Free Cash Flow fell to -$2.1 million in Q1 2026 per NNVC's latest filing, from -$2.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.0 million in Q3 2022 and troughed at -$2.6 million in Q3 2024.
- A 5-year average of -$1.7 million and a median of -$1.7 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow jumped 40.52% in 2022, then tumbled 121.09% in 2024.
- Over 5 years, Free Cash Flow stood at -$1.4 million in 2022, then retreated by 24.53% to -$1.7 million in 2023, then dropped by 29.39% to -$2.2 million in 2024, then advanced by 10.81% to -$2.0 million in 2025, then decreased by 2.97% to -$2.1 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$2.1 million, -$2.0 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | -1.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.06 Mn |
| Mar 31, 2026 | -2.06 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -2.24 Mn |
| Dec 31, 2024 | -2.24 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Jun 30, 2024 | -1.63 Mn |
| Jun 30, 2024 | -1.63 Mn |
| Mar 31, 2024 | -1.93 Mn |
| Mar 31, 2024 | -1.93 Mn |
| Dec 31, 2023 | -1.73 Mn |
| Dec 31, 2023 | -1.73 Mn |